Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
LNTH 
Lantheus Holdings Inc (LNTH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: LNTH (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
13 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $88
1 Year Target Price $88
| 9 | Strong Buy |
| 3 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -30.12% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.77B USD | Price to earnings Ratio 14.76 | 1Y Target Price 88 |
Price to earnings Ratio 14.76 | 1Y Target Price 88 | ||
Volume (30-day avg) 13 | Beta 0.14 | 52 Weeks Range 47.25 - 118.21 | Updated Date 08/29/2025 |
52 Weeks Range 47.25 - 118.21 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 3.76 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-06 | When - | Estimate 1.67 | Actual 1.57 |
Profitability
Profit Margin 17.82% | Operating Margin (TTM) 23.27% |
Management Effectiveness
Return on Assets (TTM) 13.34% | Return on Equity (TTM) 24.71% |
Valuation
Trailing PE 14.76 | Forward PE 9.48 | Enterprise Value 3693597269 | Price to Sales(TTM) 2.48 |
Enterprise Value 3693597269 | Price to Sales(TTM) 2.48 | ||
Enterprise Value to Revenue 2.43 | Enterprise Value to EBITDA 8.08 | Shares Outstanding 67994200 | Shares Floating 63180843 |
Shares Outstanding 67994200 | Shares Floating 63180843 | ||
Percent Insiders 2.28 | Percent Institutions 117.2 |
Upturn AI SWOT
Lantheus Holdings Inc
Company Overview
History and Background
Lantheus Holdings Inc. was founded in 1956 as New England Nuclear. Over the years, it evolved through various acquisitions and divestitures, ultimately becoming Lantheus Holdings Inc., a focused player in precision diagnostics and therapies. The company has transformed to focus on the development, manufacture, and commercialization of diagnostic and therapeutic products.
Core Business Areas
- Precision Diagnostics: Develops, manufactures, and commercializes diagnostic imaging agents that help physicians to visualize and interpret images, leading to more accurate and earlier diagnoses. These products use Positron Emission Tomography (PET), Single-Photon Emission Computed Tomography (SPECT), and other imaging modalities.
- Strategic Therapeutics: Focuses on the development and commercialization of therapeutic products that target specific diseases and conditions. This segment represents future growth potential leveraging diagnostic insights.
Leadership and Structure
Mary Anne Heino serves as the President and Chief Executive Officer. The company operates with a structured management team overseeing various functional areas including R&D, commercial operations, manufacturing, and finance. It is a publicly traded company with a Board of Directors.
Top Products and Market Share
Key Offerings
- DEFINITY: A ultrasound contrast agent used in echocardiography. Competitors: GE Healthcare, Bracco Diagnostics. Market share data not publicly broken out. Revenues are approximately $255 Million in 2023.
- PYLARIFY: A PSMA-targeted PET imaging agent used to detect prostate cancer. Competitors: Blue Earth Diagnostics, Progenics Pharmaceuticals (now part of Lantheus itself through acquisition). PYLARIFY is a growth driver for Lantheus. Revenues are approximately $258 Million in 2023.
- TechneLite: A technetium Tc 99m generator used for SPECT imaging. Revenue is approximately $100 Million in 2023. Competitors include NorthStar Medical Radioisotopes and Curium
Market Dynamics
Industry Overview
The radiopharmaceutical and medical imaging market is experiencing growth due to aging populations, increasing prevalence of chronic diseases (like cancer), technological advancements in imaging modalities, and growing demand for personalized medicine. There is also significant growth in radiotherapeutics.
Positioning
Lantheus is a key player in the medical imaging industry with a focus on diagnostic and therapeutic radiopharmaceuticals. Its strength lies in its established product portfolio, distribution network, and expertise in radiopharmaceutical development and manufacturing.
Total Addressable Market (TAM)
The global radiopharmaceutical market is estimated to be over $7 billion and is expected to grow significantly over the next decade. Lantheus is well-positioned to capture a meaningful share of this expanding market through its diagnostics and therapeutics.
Upturn SWOT Analysis
Strengths
- Established product portfolio
- Strong distribution network
- Expertise in radiopharmaceutical development and manufacturing
- Strategic acquisitions enhancing pipeline
- Experienced leadership team
Weaknesses
- Dependence on key products
- Vulnerability to generic competition
- Regulatory hurdles in product development and approval
- Reliance on third-party suppliers for raw materials
- Debt levels could be a concern.
Opportunities
- Expanding into new therapeutic areas
- Developing innovative imaging agents
- Leveraging partnerships for growth
- Increasing adoption of precision medicine
- International expansion
Threats
- Competition from larger pharmaceutical companies
- Pricing pressures and reimbursement challenges
- Technological advancements rendering existing products obsolete
- Supply chain disruptions
- Changing regulatory landscape
Competitors and Market Share
Key Competitors
- GE
- BRLI
Competitive Landscape
Lantheus benefits from its expertise in radiopharmaceuticals. GE is much larger but has different operational dynamics to deal with. BRLI is directly competitive with PYLARIFY.
Major Acquisitions
Progenics Pharmaceuticals
- Year: 2019
- Acquisition Price (USD millions): 400
- Strategic Rationale: Expanded Lantheus's pipeline of molecular imaging and therapeutic agents.
Growth Trajectory and Initiatives
Historical Growth: Lantheus has experienced significant growth in recent years, driven by the successful launch and adoption of PYLARIFY and continued performance of DEFINITY.
Future Projections: Analysts project continued revenue growth in the coming years, driven by PYLARIFY adoption, new product launches, and expansion into new markets.
Recent Initiatives: Recent initiatives include strategic acquisitions to expand the product pipeline (e.g., Progenics), investments in R&D, and efforts to enhance manufacturing capabilities.
Summary
Lantheus Holdings is a strong company, specializing in precision diagnostics and therapeutic radiopharmaceuticals. The company's growth is driven by products like PYLARIFY, and is focused on expansion of strategic therapeutics. One thing the company needs to keep in mind is to be on the lookout for regulatory hurdles in product development, and supply chain disruptions.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Lantheus Holdings Inc. Investor Relations, SEC Filings, Analyst Reports
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Market conditions are always changing.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lantheus Holdings Inc
Exchange NASDAQ | Headquaters Bedford, MA, United States | ||
IPO Launch date 2015-06-25 | CEO & Director Mr. Brian A. Markison | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 808 | Website https://www.lantheus.com |
Full time employees 808 | Website https://www.lantheus.com | ||
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.